Open label, phase I/II study of the safety, tolerability and efficacy of intravenous alpha-1 antitrypsin (AAT) [glassiac] in type 1 diabetes

Authors
Category Primary study
ConferenceDiabetes Technology and Therapeutics
Year 2013
This article has no abstract
Epistemonikos ID: d2b20ea7b1be0639e0a0c27f1b6f66ffafd3707a
First added on: Apr 30, 2026